The drug and medical device maker Johnson & Johnson kicked off the healthcare earnings season with a better-than-anticipated ...

By Michael Erman and Patrick Wingrove (Reuters) -Johnson & Johnson halved its expectations for costs this year related to new ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Johnson & Johnson raised its full-year sales forecast on Wednesday after beating estimates for second-quarter profit on ...

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...

Johnson & Johnson is leading the S&P 500 and the Dow Jones Industrial Average after the drugmaker slashed its estimate for the impact of tariffs in 2025 and raised its outlook. The company’s stock is ...

Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. "Today's strong results reflect the depth and strength of Johnson & Johnson's uniquely diversified business operating ...